ENDP - Endo unit gains right to commercialize Netherton Syndrome treatment in Canada
- Endo International ( NASDAQ: ENDP ) subsidiary Endo Ventures has brokered a license and distribution agreement with Quoin Pharmaceuticals giving the former exclusive rights to QRX003 for Netherton Syndrome in Canada.
- Under the agreement, Endo ( ENDP ) affiliate Paladin Labs will commercialize QRX003 in Canada upon regulatory approval. Quoin will manufacture and supply the product.
- Financial terms were not disclosed.
- QRX003, which is a lotion to treat the rare skin disorder, recently entered phase 1 testing.
- Check out why Seeking Alpha contributor CashFlow Hunter just gave Endo ( ENDP ) a strong sell rating.
For further details see:
Endo unit gains right to commercialize Netherton Syndrome treatment in Canada